Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML - PubMed (original) (raw)
Clinical Trial
. 2009 Sep 10;114(11):2220-31.
doi: 10.1182/blood-2009-03-213389. Epub 2009 Jul 8.
Affiliations
- PMID: 19587375
- DOI: 10.1182/blood-2009-03-213389
Free article
Clinical Trial
Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML
Susanne Schnittger et al. Blood. 2009.
Free article
Abstract
Nucleophosmin (NPM1)-mutated acute myeloid leukemia (AML), which is recognized as a provisional entity in the World Health Organization 2008 classification of myeloid neoplasms, accounts for 30% of AML. We analyzed 1227 diagnostic and follow-up samples in 252 NPM1-mutated AML patients with 17 different NPM1 mutation-specific real-time quantitative polymerase chain reaction (RQ-PCR) assays. Paired diagnostic/relapse samples of 84 patients revealed stable NPM1 mutations in all cases, suggesting that they are pathogenetically early events and thus applicable for minimal residual disease detection. A total of 47 relapses were predictable because of an NPM1 mutation level (%NPM1/ABL1) increase of at least 1 log or in 15 cases because of NPM1 mutation levels not decreasing less than 3 log ranges. A high prognostic value of NPM1 levels was shown for 4 different intervals after therapy was initiated. Furthermore, thresholds of 0.1 and 0.01%NPM1/ABL1 during/after treatment discriminated between prognostic subgroups. Univariate analyses, including age, white blood cell count, blast count, CD34 positivity, FLT3 mutations status, FAB type, karyotype, NPM1 mutation type, and pretreatment NPM1 mutational level, showed that, besides NPM1 mutation level, only age and FLT3-LM mutation status were prognostically significant for EFS. Multivariate analysis, including age, FLT3-LM status, and NPM1 mutation level at different time points, demonstrated that NPM1 level was the most relevant prognostic factor during first-line treatment. Similar results were obtained in patients undergoing second-line chemotherapy or allogeneic stem cell transplantation.
Similar articles
- CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
Dang H, Chen Y, Kamel-Reid S, Brandwein J, Chang H. Dang H, et al. Hum Pathol. 2013 Oct;44(10):2038-46. doi: 10.1016/j.humpath.2013.03.007. Epub 2013 May 21. Hum Pathol. 2013. PMID: 23701943 - FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
Rezaei N, Arandi N, Valibeigi B, Haghpanah S, Khansalar M, Ramzi M. Rezaei N, et al. Turk J Haematol. 2017 Dec 1;34(4):300-306. doi: 10.4274/tjh.2016.0489. Epub 2017 Mar 15. Turk J Haematol. 2017. PMID: 28294102 Free PMC article. - The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML.
Shayegi N, Kramer M, Bornhäuser M, Schaich M, Schetelig J, Platzbecker U, Röllig C, Heiderich C, Landt O, Ehninger G, Thiede C; Study Alliance Leukemia (SAL). Shayegi N, et al. Blood. 2013 Jul 4;122(1):83-92. doi: 10.1182/blood-2012-10-461749. Epub 2013 May 8. Blood. 2013. PMID: 23656730 - Minimal/Measurable Residual Disease Monitoring in _NPM1_-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives.
Forghieri F, Comoli P, Marasca R, Potenza L, Luppi M. Forghieri F, et al. Int J Mol Sci. 2018 Nov 6;19(11):3492. doi: 10.3390/ijms19113492. Int J Mol Sci. 2018. PMID: 30404199 Free PMC article. Review. - Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.
Port M, Böttcher M, Thol F, Ganser A, Schlenk R, Wasem J, Neumann A, Pouryamout L. Port M, et al. Ann Hematol. 2014 Aug;93(8):1279-86. doi: 10.1007/s00277-014-2072-6. Epub 2014 May 7. Ann Hematol. 2014. PMID: 24801015 Review.
Cited by
- The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively.
Heiblig M, Duployez N, Marceau A, Lebon D, Goursaud L, Plantier I, Stalnikiewich L, Cambier N, Balsat M, Fossard G, Labussière-Wallet H, Barraco F, Ducastelle-Lepretre S, Sujobert P, Huet S, Hayette S, Ghesquières H, Thomas X, Preudhomme C. Heiblig M, et al. Cancers (Basel). 2021 Apr 29;13(9):2156. doi: 10.3390/cancers13092156. Cancers (Basel). 2021. PMID: 33947035 Free PMC article. - Clinical implications of molecular markers in acute myeloid leukemia.
Kayser S, Levis MJ. Kayser S, et al. Eur J Haematol. 2019 Jan;102(1):20-35. doi: 10.1111/ejh.13172. Epub 2018 Oct 23. Eur J Haematol. 2019. PMID: 30203623 Free PMC article. Review. - Clinical Use of Measurable Residual Disease in Acute Myeloid Leukemia.
Roug AS, Ommen HB. Roug AS, et al. Curr Treat Options Oncol. 2019 Mar 14;20(4):28. doi: 10.1007/s11864-019-0627-4. Curr Treat Options Oncol. 2019. PMID: 30874904 Review. - Multiplex accurate sensitive quantitation (MASQ) with application to minimal residual disease in acute myeloid leukemia.
Moffitt AB, Spector MS, Andrews P, Kendall J, Alexander J, Stepansky A, Ma B, Kolitz J, Chiorazzi N, Allen SL, Krasnitz A, Wigler M, Levy D, Wang Z. Moffitt AB, et al. Nucleic Acids Res. 2020 Apr 17;48(7):e40. doi: 10.1093/nar/gkaa090. Nucleic Acids Res. 2020. PMID: 32083660 Free PMC article. - High _NPM1_-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML.
Patel SS, Kuo FC, Gibson CJ, Steensma DP, Soiffer RJ, Alyea EP 3rd, Chen YA, Fathi AT, Graubert TA, Brunner AM, Wadleigh M, Stone RM, DeAngelo DJ, Nardi V, Hasserjian RP, Weinberg OK. Patel SS, et al. Blood. 2018 Jun 21;131(25):2816-2825. doi: 10.1182/blood-2018-01-828467. Epub 2018 May 3. Blood. 2018. PMID: 29724895 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous